Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases, announced today a proposed underwritten public offering of shares of its common stock and accompanying warrants to purchase common stock. The company intends to use the net proceeds to support the continued clinical development of its lead drug candidate, buntanetap, in a Phase 3 Alzheimer's disease study, as well as for working capital and general corporate purposes.
Buntanetap (formerly posiphen) is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients with Alzheimer's disease (AD) and Parkinson's disease (PD).
The announcement comes as the company advances its clinical program. According to the press release, the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The company has not disclosed the number of shares or warrants to be offered or the price range.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is focused on developing therapies for neurodegenerative diseases. The company's drug development pipeline includes buntanetap for both AD and PD. For more information, visit the company's website at www.annovisbio.com.
This offering is significant for investors as it will provide Annovis with additional capital to fund the costly Phase 3 trials required for regulatory approval. If successful, buntanetap could offer a new treatment option for millions of patients suffering from Alzheimer's and Parkinson's diseases, potentially addressing a critical unmet medical need. The proceeds will also support the company's working capital and general corporate purposes, ensuring operational stability during the development process.
For the latest news and updates relating to Annovis Bio, visit the company's newsroom at https://ibn.fm/ANVS.
